Add Formweb to your mobile device
Approved Formulary
Search results for:
pregabalin
pregabalin
Brand names: Lyrica
| Form | Strength |
|---|---|
| CAPSULE, ORAL | 25 mg; 50 mg; 75 mg |
Display Anticonvulsants, Miscellaneous Class:
281292
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | pregabalin (Lyrica) |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | antiepileptics ⇄ History of falls or fractures |
| Rationale | May cause ataxia, impaired psychomotor function, syncope, or additional falls. If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures. (i.e., anticholinergics, selected antidepressants, antiepileptics, antipsychotics, sedative/hypnotics including benzodiazepines and, Nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids) and implement other strategies to reduce fall risk. |
| Recommendation | Avoid except for seizures and mood disorders. |
| Quality of evidence: High, Strength of Recommendation: Strong | |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | antiepileptics (including gabapentinoids) ⇄ CNS-active agents |
| Risk Rationale | Increased risk of falls and of fracture with the concurrent use of ≥3 CNS-active agents (antiepileptics including gabapentinoids, antidepressants, antipsychotics, benzodiazepines, Nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids, and skeletal muscle relaxants). |
| Recommendation | Avoid concurrent use of ≥3 CNS-active drugs Click for list; minimize the number of CNS-active drugs. |
| Quality of evidence: High, Strength of Recommendation: Strong | |
| Criteria 5: medications that should be avoided or have their dosage reduced with varying levels of kidney function in older adults. (Table 6) | |
| CrCl (mL/min) at which action is required | <60 |
| Rationale | CNS adverse effects |
| Recommendation | Reduce dose |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
Last updated: Sep. 19, 2025